If two heads are better than one when it comes to problem solving, it stands to reason that hundreds of the best and brightest minds can accomplish great things.
The Stanford Cancer Institute brings together over 400 faculty members from four schools and more than 30 departments in a collaborative, interdisciplinary effort to improve the diagnosis, treatment and prevention of cancer.
These physicians, basic and translational researchers, clinical trial experts and population scientists are developing novel prevention and detection strategies and creating and delivering innovative therapies from immunotherapy to new, targeted drug treatments for many types of cancer. More than 250 cancer clinical trials are recruiting people from California and beyond.
The institute holds an annual comprehensive cancer research training program, and it oversees doctoral programs in cancer biology, as well as the education and training of the next generation of clinician researchers.
The institute also is developing a research program in cancer engineering, and recently invested in the new Department of Epidemiology and Population Health.
In 2016, the National Cancer Institute designated the Stanford Cancer Institute a Comprehensive Cancer Center — an elite status earned through a competitive review process by institutions demonstrating an integrated, wide range of cancer research spanning from basic laboratory research to translational, clinical and population-based sciences.
These efforts mean researchers are poised to supplement stellar cancer care with advanced cancer treatments. “This is an incredibly opportune time,” said the institute’s director Steven Artandi, MD, PhD.